欧盟建议Libtayo对高风险皮肤癌患者进行外科手术后治疗,发现重症复发风险低68%。 The EU recommended Libtayo for high-risk skin cancer patients post-surgery, showing 68% lower recurrence risk.

欧洲医药署(ECMP)建议批准Regeneron’s Libtayo(cemiplimab)作为手术后和辐射后高危险切口细胞恶性肿瘤的辅助治疗。 The European Medicines Agency’s CHMP has recommended approval of Regeneron’s Libtayo (cemiplimab) as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma after surgery and radiation. 该决定以C-POST第三阶段审判为基础,表明与安慰剂相比,复发或死亡风险减少了68%,洛科区域复发率和远期复发率较低。 The decision, based on the Phase 3 C-POST trial, showed a 68% reduction in recurrence or death risk compared to placebo, with lower rates of locoregional and distant recurrence. 预计欧洲联盟委员会将在2025年10月美国林业发展局核准后很快作出最后决定。 The European Commission is expected to make a final decision soon, following the U.S. FDA’s October 2025 approval.